LDN-025

N/A

Report date: 2024/01/09 12:13:53
NMEFirst In Class

Base Information

Drug NameLDN-025
Drug Alias NameLDN-025
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionEpithelial sodium channel inhibitors
TargetsEpithelial sodium channel
Therapy Area/IndicationsCystic Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryHungary
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLadon Therapeutics Kft
China Registration ClassN/A

Develop Information

Active CompaniesLadon Therapeutics Kft
Inactive CompaniesN/A
Active IndicationsCystic Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A